ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANAB AnaptysBio Inc

19.27
0.09 (0.47%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
AnaptysBio Inc ANAB NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.09 0.47% 19.27 10:00:00
Open Price Low Price High Price Close Price Previous Close
19.01 18.71 19.29 19.27 19.18
more quote information »

Recent News

Date Time Source Heading
24/4/202423:00PRNUSActym Therapeutics Appoints Thomas Smart as CEO
12/3/202407:41EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/3/202407:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
12/3/202407:19EDGAR2Form 8-K - Current report
01/3/202401:15GLOBEAnaptys to Present at TD Cowen’s 44th Annual Health Care..
15/2/202402:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202400:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202401:15GLOBEAnaptys to Present at Guggenheim’s 6th Annual Biotechnology..
10/1/202411:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202411:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202409:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202409:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:09EDGAR2Form 8-K - Current report
28/11/202308:17EDGAR2Form 8-K - Current report
28/11/202308:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
08/11/202308:15GLOBEAnaptys Named a BioSpace 2024 Best Places to Work Winner
03/11/202307:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202307:18EDGAR2Form 8-K - Current report
03/11/202307:15GLOBEAnaptys Announces Third Quarter 2023 Financial Results and..
02/11/202300:15GLOBEAnaptys Announces Participation in November Investor..
26/10/202307:43EDGAR2Form 8-K - Current report
12/10/202300:15GLOBEAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist..
11/10/202300:01EDGAR2Form 8-K - Current report
09/10/202323:43DJNAnaptys Sees Positive Trial Results for Imsidolimad..
09/10/202323:15GLOBEAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist,..
09/10/202323:00GLOBEAnaptys Announces Positive Top-Line Phase 3 Clinical Trial..
19/9/202308:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202308:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202308:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/9/202306:18EDGAR2Form 8-K - Current report
19/9/202306:15GLOBEAnaptysBio Announces Appointment of John Orwin as Chairman..
12/9/202323:15GLOBEAnaptysBio to Present at the Stifel 2023 Immunology and..
08/8/202306:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:18EDGAR2Form 8-K - Current report
08/8/202306:15GLOBEAnaptysBio Announces Second Quarter 2023 Financial..
01/8/202304:27DJNAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy..
01/8/202303:34GLOBEAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI..
31/5/202306:15GLOBEAnaptysBio Announces Participation in Upcoming Investor..
12/5/202306:15GLOBEAnaptysBio Announces First Quarter 2023 Financial Results..
02/5/202323:15GLOBEAnaptysBio Announces British Journal of Dermatology..

Your Recent History

Delayed Upgrade Clock